Introduction: There is still limited information available in France to assess the burden of parkinsonian syndromes (PS), of which Parkinson’s disease is the most common cause, in terms of prevalence, healthcare utilization, or mortality. The objective of this study was to describe PS-related mortality in France. Methods: The analyses presented in this report concern deaths that occurred in France in 2010, extracted from the national CépiDc-Inserm database. Deaths for which the death certificate listed a PD code according to the International Classification of Diseases (ICD-10) (G20 to G23, except G21.0 alone, or F023) as the primary or associated cause were selected. Trends in mortality rates were examined over the 2000–2010 period. Other causes of death listed on these death certificates were examined. Finally, the primary causes of death among individuals whose death certificates listed a PD as an associated cause were compared to those observed in individuals who died without a mention of PD. Results: Among the 514,084 deaths reported in 2010 among individuals aged 50 and older, 1.9% listed MS. Compared to those who died without a mention of MS, those who died with MS were, on average, older at the time of death (82.7 vs. 79.5 years). After adjusting for age, individuals who died with MS were significantly more likely to be male (56.6% vs. 49.8%), more likely to be married (48.3% vs. 40.6%), and were twice as likely to die in a nursing home (23.2% vs. 12.0%). The age-standardized mortality rate in 2010 was 41.1 per 100,000 person-years (65.3 among men and 27.7 among women). Between 2000 and 2010, age-standardized mortality rates remained stable. Compared to individuals who died without a mention of PD, the distribution of primary causes of death in cases where PD is mentioned only as a contributing cause shows, after adjustment for age and sex, that people with Parkinson’s disease died more often with dementia (ORa=1.62, 95% CI [1.46–1.80]), another nervous system disease (ORa=2.18 [1.81–2.61]), aspiration pneumonia (ORa=2.34 [1.94–2.82]), venous thromboembolic disease (ORa=1.45 [1.12–1.87]), cerebrovascular disease (ORa=1.44 [1.30–1.60]), or a fall (ORa=2.21 [1.83–2.69]). Conversely, the risk of dying from an invasive tumor is reduced among this group (ORa=0.44 [0.40–0.48]). Conclusion: This study identified and characterized individuals who died with a PS in France in 2010 and documented the causes of their deaths. However, due to the underreporting of PS in death certificates—which may itself have changed over time—caution is warranted in interpreting these results.